Candel Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
CADL$9.49+8.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
| JUNE 30,2026(Unaudited) | DECEMBER 31,2025 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $201,565 | $119,731 |
| Prepaid expenses and other current assets | 2,593 | 1,658 |
| Total current assets | 204,158 | 121,389 |
| Fixed assets, net | 2,002 | 1,642 |
| Lease right of use assets | 1,475 | 1,661 |
| Restricted cash | 416 | 416 |
| Other assets | 98 | 87 |
| Total assets | $208,149 | $125,195 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $5,154 | $1,129 |
| Accrued expenses | 6,981 | 7,334 |
| Current portion of lease liability | 461 | 445 |
| Other current liabilities | 89 | 89 |
| Total current liabilities | 12,685 | 8,997 |
| Deferred revenue | 45 | 89 |
| Term loan | 46,744 | 46,122 |
| Other long-term debt | 1,087 | 1,008 |
| Lease liability, net of current portion | 1,225 | 1,459 |
| Warrant liabilities | 20,233 | 15,598 |
| Total liabilities | 82,019 | 73,273 |
| Commitments and contingencies (Note 15) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.01 par value; 10,000,000 shares authorized at June 30, 2026 and December 31, 2025; no shares issued or outstanding at June 30, 2026 and December 31, 2025. | — | — |
| Common stock, $0.01 par value; 150,000,000 shares authorized at June 30, 2026 and December 31, 2025; 76,240,884 and 55,020,911 shares issued at June 30, 2026 and December 31, 2025, respectively; 76,118,276 and 54,898,303 shares outstanding at June 30, 2026 and December 31, 2025, respectively. | 761 | 550 |
| Treasury stock (at cost) | (448) | (448) |
| Additional paid-in capital | 403,970 | 282,207 |
| Accumulated deficit | (278,153) | (230,387) |
| Total stockholders’ equity | 126,130 | 51,922 |
| Total liabilities and stockholders’ equity | $208,149 | $125,195 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.